{"id":7806,"date":"2020-06-25T13:02:15","date_gmt":"2020-06-25T20:02:15","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=7806"},"modified":"2021-03-26T13:04:05","modified_gmt":"2021-03-26T20:04:05","slug":"tocilizumab-in-patients-with-severe-covid-19-a-retrospective-cohort-study","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/06\/25\/tocilizumab-in-patients-with-severe-covid-19-a-retrospective-cohort-study\/","title":{"rendered":"Tocilizumab in Patients with Severe COVID-19:\u00a0A Retrospective\u00a0Cohort Study"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"34\" data-aria-posinset=\"2019\" data-aria-level=\"1\"><span data-contrast=\"auto\">T<\/span><span data-contrast=\"auto\">ocilizumab treatment<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">among patients with severe COVID-19<\/span><span data-contrast=\"auto\">, whether administered intravenously or subcutaneously, was associated with a reduced risk of invasive mechanical ventilation or death (adjusted HR = 0.61, 95% CI: 0.40-0.92)<\/span><span data-contrast=\"auto\">\u00a0in a<\/span><span data-contrast=\"auto\">\u00a0retrospective study (n=544)<\/span><span data-contrast=\"auto\">.<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">However, a significantly larger proportion of tocilizumab recipients were diagnosed with new infections compared with patients treated with standard of care (13% vs 4%, p &lt; 0.0001).<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Guaraldi et al. (June 24, 2020). Tocilizumab in Patients with Severe COVID-19:\u00a0A Retrospective\u00a0Cohort Study.\u00a0The Lancet\u00a0Rheumatology.\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/S2665-9913(20)30173-9\"><span data-contrast=\"none\">https:\/\/doi.org\/10.1016\/S2665-9913(20)30173-9<\/span><\/a><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tocilizumab treatment\u00a0among patients with severe COVID-19, whether administered intravenously or subcutaneously, was associated with a reduced risk of invasive mechanical ventilation or death (adjusted HR = 0.61, 95% CI: 0.40-0.92)\u00a0in a\u00a0retrospective study (n=544).\u00a0However, a significantly larger proportion of tocilizumab recipients were diagnosed with new infections compared with patients treated with standard of care (13% vs&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/06\/25\/tocilizumab-in-patients-with-severe-covid-19-a-retrospective-cohort-study\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[19],"class_list":["post-7806","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=7806"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7806\/revisions"}],"predecessor-version":[{"id":7807,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7806\/revisions\/7807"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=7806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=7806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=7806"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=7806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}